Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Bone Care International
Madison, Wisconsin, USA
- Ownership
- Private
- Development stage
- Other
01
Overview
Bone Care International was a specialty pharmaceutical company focused on the development and commercialization of novel therapeutic products for the treatment of nephrology, oncology, and dermatology. The company's primary focus was on its proprietary pro-vitamin D hormone technology, specifically its lead product Hectorol (doxercalciferol). Hectorol was approved for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and those with Stage 3 or 4 CKD. The company was acquired by Genzyme Corporation in 2005 for approximately $600 million to bolster Genzyme's renal portfolio.
- Therapeutic areas
- EndocrinologyNephrologyDermatology
- Modalities
- Small moleculeHormone
- Industry
- Biotech
02
Partnerships
Medice
Beyond the preview
Go deeper on Bone Care International.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bone Care International.